ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Bupi Yishen formula may prevent kidney fibrosis by modulating fatty acid metabolism in renal tubules

Liu, Bingran; Jie, Xina; Deng, Jiankun; Zhang, Simeng; Lu, Fuhua; Liu, Xusheng*; Zhang, Difei*广东省人民医院; 广州中医药大学
PHYTOMEDICINE2023-6DOI: 10.1016/j.phymed.2023.154767
2被引21阅读
引用收藏
分享

摘要

Background: Bupi Yishen formula (BYF), a traditional Chinese herbal mixture, has demonstrated better effectiveness than Losartan in preserving renal function and preventing composite severe adverse outcomes in patients with advanced chronic kidney disease (CKD) in a recent randomized controlled trial. Prior studies have shown that BYF exerts anti-inflammatory and anti-fibrotic effects in the kidneys of CKD models, but the underlying mechanisms have not been fully elucidated. @@@ Purpose: The aim of this study was to investigate the protective effects of BYF administration on profibrotic phenotypic changes in the kidney and to elucidate its fundamental mechanisms of action. @@@ Methods: Adenine and 5/6 nephrectomy rat models were administered with two doses of BYF extract (15 or 30 g/kg/d) by intragastric administration, and Losartan treatment was used as a positive control group. The relationship between BYF renoprotection and restoration of fatty acid dysregulation was examined using the two fibrosis models and TGFb1-induced human tubular HK2 cells. Transcriptomic profiles of the fibrotic kidneys obtained from adenine-induced CKD rats were used to identify the key mechanisms that are affected by BYF intervention. Human relevance and clinical implications were established by re-analysis of the microarray databases of CKD patients and immunostaining on human biopsy specimens. @@@ Results: BYF effectively prevented kidney histological damage and ameliorated renal malfunction in the adenine rat model of CKD. BYF robustly attenuated the significant increase in profibrotic and proapoptotic markers in fibrotic kidneys of adenine-induced CKD rats. Transcriptomic analyses of the fibrotic kidneys of the adenine rats identified fatty acid metabolism as the key dysregulated pathway affected by BYF prevention. BYF significantly reversed defective fatty acid oxidation (FAO) and the intracellular lipids accumulation in the fibrotic kidneys induced by 5/6 nephrectomy. Furthermore, BYF prevented dysfunctional fatty acid metabolism, which were associated with the significant improvement of TGFb1-induced profibrotic changes in HK2 human proximal tubular cells. Furthermore, analyses of kidney microarray databases and biopsy specimens of CKD patients suggested that FAO defect is common in CKD in humans. @@@ Conclusion: Our exploratory study found that BYF may exert protective effects on renal fibrosis by regulating the fatty acid metabolism of renal tubular cells, which may be a key mechanism for preventing kidney fibrosis in CKD.

学科与关键词

关键词
Bupi Yishen formulaKidney fibrosisFatty acid metabolismRenal tubular epithelial cellsChronic kidney disease
相关
加载中…
  • Protective effects of the Bupi Yishen formula on renal fibrosis through PI3K/AKT signaling inhibition
    Liu, Bingran; Deng, Jiankun; Jie, Xina; Lu, Fuhua; Liu, Xusheng*; Zhang, Difei*Journal of Ethnopharmacology, 2022, 293: 115242.被引 4
  • Jian-Pi-Yi-Shen Formula Ameliorates Oxidative Stress, Inflammation, and Apoptosis by Activating the Nrf2 Signaling in 5/6 Nephrectomized Rats
    Zhou, Fanyuan; Zou, Xiaohu; Zhang, Jing; Wang, Ziwei; Yang, Yajun*; Wang, Dongtao*Frontiers in Pharmacology, 2021, 12: 630210.被引 15
  • Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease
    Mao Wei; Zhang Lei; Zou Chuan; Li Chuang; Wu Yifan; Su Guobin; Guo Xinfeng; Wu Yuchi; Lu Fuhua; Lin Qizhan; Wang Lixin; Bao Kun; Xu Peng; Zhao Daixin; Peng Yu; Liang Hui; Lu Zhaoyu; Gao Yanxiang; Jie Xina; Zhang La; Wen Zehuai*; Liu XushengBMC Complementary and Alternative Medicine, 2015, 15: 316.
查看全部 →

发表信息

论文状态
公开发表
期刊
PHYTOMEDICINE
发表日期
2023-06
卷期
第 114 卷
页码
154767
DOI
10.1016/j.phymed.2023.154767
语言
GERMAN
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81904099, 81873261, 82205106]; China Post-doctoral Science Foundation [2020M672559]; 2020 Guangdong Pro-vincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab) [2020B1212030006]; Guangzhou Basic and Applied Basic Research Foundation [2023A03J0234]; National Clinical Research Center of Kidney Disease, Jinling Hospital

作者

  • L

    Liu, Bingran (第一作者)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • J

    Jie, Xina

    2 · guangzhou univ chinese med · guangdong prov hosp

查看全部 7 位作者收起作者
  • D

    Deng, Jiankun

    2 · guangzhou univ chinese med

  • Z

    Zhang, Simeng

    2 · guangzhou univ chinese med

  • L

    Lu, Fuhua

    guangzhou univ chinese med · guangdong prov hosp · 2

  • L

    Liu, Xusheng (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

  • Z

    Zhang, Difei (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417